Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

Obesity is an epidemic in the United States, but more people are shedding pounds with the help of weight loss drugs.

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the field of ...

GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza, Wegovy started as a way to treat diabetes but have since become popular for weight loss.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

More and more Americans are turning to GLP-1 injections to lose weight. FOX 7 Austin's Rebecca Thomas spoke to an Austin ...

as prior studies have reported GLP-1 receptor agonist discontinuation rates of up to 81%, Emanuel's group wrote. They added that the links between weight loss and discontinuation and between ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic ...